The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia

The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia

<p><strong>Background:</strong> Dementia is one of the milestones of advanced Parkinson’s disease (PD), with its neuropathological substrate still being a matter of debate, particularly regarding its potential mechanistic implications.</p> <p><strong>Objective:<...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Compta, Y, Parkkinen, L, Kempster, P, Selikhova, M, Lashley, T, Holton, J, Lees, A, Revesz, T
Format:	Journal article
Wydane:	Karger 2013

Podobne zapisy

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
od: Compta, Y, i wsp.
Wydane: (2011)

Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia
od: Rebecca L. Miller, i wsp.
Wydane: (2022-02-01)

Parkinson’s Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron
od: Jiajun Han, i wsp.
Wydane: (2021-10-01)

Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis
od: Simone A. van den Berge, i wsp.
Wydane: (2012-01-01)

Microglia phenotypes are associated with subregional patterns of concomitant tau, amyloid-β and α-synuclein pathologies in the hippocampus of patients with Alzheimer’s disease and dementia with Lewy bodies
od: Sonja Fixemer, i wsp.
Wydane: (2022-03-01)

Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia
od: Parkkinen, L, i wsp.
Wydane: (2004)

Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease
od: Parkkinen, L, i wsp.
Wydane: (2011)

Plasma extracellular vesicle tau, β-amyloid, and α-synuclein and the progression of Parkinson’s disease: a follow-up study
od: Lung Chan, i wsp.
Wydane: (2023-01-01)

α-synuclein genetic variability: A biomarker for dementia in Parkinson disease
od: Guella, I, i wsp.
Wydane: (2016)

Phosphatases of α-synuclein, LRRK2 and tau: important players in the phosphorylation-dependent pathology of Parkinsonism
od: Jean-Marc eTaymans, i wsp.
Wydane: (2014-11-01)

Can olfactory bulb biopsy be justified for the diagnosis of Parkinson’s disease? Comments on “olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders”
od: Parkkinen, L, i wsp.
Wydane: (2008)

Does levodopa accelerate the pathologic process in Parkinson disease brain?
od: Parkkinen, L, i wsp.
Wydane: (2011)

Association of MAPT (tau) haplotype with the pathology of Parkinson's disease
od: Parkkinen, L, i wsp.
Wydane: (2013)

Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology
od: Marta Jorge-Oliva, i wsp.
Wydane: (2022-12-01)

Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance
od: Parkkinen, L, i wsp.
Wydane: (2008)

Relationship of Apolipoprotein E to Parkinson's disease-related alpha-synuclein pathology
od: Parkkinen, L, i wsp.
Wydane: (2013)

Initiation and progression of α-synuclein pathology in Parkinson’s disease
od: Tofaris, GK
Wydane: (2022)

Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms
od: Mario Meloni, i wsp.
Wydane: (2023-01-01)

Widespread and abundant α-synuclein pathology in a neurologically unimpaired subject
od: Parkkinen, L, i wsp.
Wydane: (2005)

Assessment of α-Synuclein Pathology
od: Alafuzoff, I, i wsp.
Wydane: (2008)

α-Synuclein Aggregated with Tau and β-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise
od: Simona Daniele, i wsp.
Wydane: (2018-01-01)

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein
od: Xi Li, i wsp.
Wydane: (2024-10-01)

Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology
od: Zsolt Huszár, i wsp.
Wydane: (2024-10-01)

Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies
od: Agathe Vrillon, i wsp.
Wydane: (2024-07-01)

Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain
od: Tapiola, T, i wsp.
Wydane: (2009)

Amyloid β,α-Synuclein and Amyloid β‑α-Synuclein Combination Exert Significant but Different Alterations in Inflammatory Response Profile in Differentiated Human SH-SY5Y Cells
od: Ebru Keskin, i wsp.
Wydane: (2023-11-01)

Role of α- and β-Synucleins in the Axonal Pathology of Parkinson’s Disease and Related Synucleinopathies
od: Akio Sekigawa, i wsp.
Wydane: (2015-05-01)

Sensitive detection of pathological seeds of α-synuclein, tau and prion protein on solid surfaces.
od: Christina D Orrú, i wsp.
Wydane: (2024-04-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
od: Niklas Mattsson‐Carlgren, i wsp.
Wydane: (2021-05-01)

Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entity.
od: Tofaris, G, i wsp.
Wydane: (2007)

Oligomerization by co-assembly of β-amyloid and α-synuclein
od: Jin Ryoun Kim
Wydane: (2023-03-01)

Tyrosine phosphatase STEP61 in human dementia and in animal models with amyloid and tau pathology
od: Deonne Taylor, i wsp.
Wydane: (2023-01-01)

Disentangling the relationship between Lewy bodies and nigral neuronal loss in Parkinson's disease
od: O'Sullivan, S, i wsp.
Wydane: (2011)

Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease
od: Nai-Ching Chen, i wsp.
Wydane: (2020-04-01)

Autoantibody profiles in Alzheimer´s, Parkinson´s, and dementia with Lewy bodies: altered IgG affinity and IgG/IgM/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns
od: Luisa Knecht, i wsp.
Wydane: (2024-12-01)

The Role of α-Synuclein and LRRK2 in Tau Phosphorylation
od: Fumitaka Kawakami, i wsp.
Wydane: (2015-01-01)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
od: Joseph Therriault, i wsp.
Wydane: (2021-10-01)

Novel Mannitol-Based Small Molecules for Inhibiting Aggregation of α-Synuclein Amyloids in Parkinson's Disease
od: Ashim Paul, i wsp.
Wydane: (2019-03-01)

The Non-amyloidal Component Region of α-Synuclein Is Important for α-Synuclein Transport Within Axons
od: Eric N. Anderson, i wsp.
Wydane: (2020-01-01)

Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson’s Disease: Who’s on First?
od: Michela Zaltieri, i wsp.
Wydane: (2015-01-01)